Noronha, Vanita
Patil, Vijay
Menon, Nandini
Kalra, Devanshi
Singh, Ajaykumar
Shah, Minit
Goud, Supriya
Jobanputra, Kunal
Nawale, Kavita
Shah, Srushti
Chowdhury, Oindrila Roy
Mathrudev, Vijayalakshmi
Jogdhankar, Shweta
Singh, Madhu Yadav
Singh, Ashish
Adak, Supriya
Sandesh, Mayuri
Arunkumar, R.
Kumar, Suman
Mahajan, Abhishek
Prabhash, Kumar http://orcid.org/0000-0001-8858-5004
Funding for this research was provided by:
Lung Cancer Consortium Asia
Article History
Received: 22 September 2023
Accepted: 28 October 2023
First Online: 21 December 2023
Declarations
:
: Vanita Noronha has received funding from Amgen (Inst); AstraZeneca (Inst); Dr. Reddy's Laboratories (Inst); INTAS (Inst); Sanofi/Aventis (Inst). Vijay Patil received funding from AstraZeneca (Inst); Eisai Germany (Inst); INTAS (Inst); Johnson & Johnson/Janssen (Inst); NATCO Pharma (Inst); Novartis (Inst). Kumar Prabhash has received funding from Alkem Laboratories (Inst); BDR Pharmaceutics (Inst); Biocon (Inst); Dr. Reddy's Laboratories (Inst); Fresenius Kabi (Inst); NATCO Pharma (Inst); Roche (Inst). None of the other authors declared any conflict of interest.